Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.…
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
Palisade Bio (NASDAQ: PALI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 0.8399 USD on 20 November 2026, down 49.4% over 52 weeks. Its 52-week range is 0.8381 USD to 2.860 USD, and it trades at the bottom of that range.
Its market capitalisation is 150.74M USD.
Palisade Bio reports return on equity of -13.0%.
It holds more cash than debt, a net cash position of 113.61M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.